Evidence map›Paper›PMID 28207809›Full record

ArticlePloS one2017

Kazakhstan can achieve ambitious HIV targets despite expected donor withdrawal by combining improved ART procurement mechanisms with allocative and implementation efficiencies.

Andrew J Shattock, Clemens Benedikt, Aliya Bokazhanova, Predrag Đurić, Irina Petrenko, Lolita Ganina, Sherrie L Kelly, Robyn M Stuart, Cliff C Kerr, Tatiana Vinichenko and 6 more

Abstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Andrew J ShattockThe Kirby Institute, University of New South Wales, Sydney, Australia.ORCID http://orcid.org/0000-0002-2285-8425
Clemens BenediktThe World Bank Group, Washington DC, United States of America.
Aliya BokazhanovaJoint United Nations Programme on HIV/AIDS, Geneva, Switzerland.
Predrag ĐurićUnited Nations Development Programme, Istanbul Regional Hub, Istanbul, Turkey.
Irina PetrenkoRepublican Center for Prevention and Control of AIDS, Almaty, Kazakhstan.
Lolita GaninaRepublican Center for Prevention and Control of AIDS, Almaty, Kazakhstan.
Sherrie L KellyThe Burnet Institute, Melbourne, Australia.
Robyn M StuartThe Kirby Institute, University of New South Wales, Sydney, Australia.
Cliff C KerrThe Kirby Institute, University of New South Wales, Sydney, Australia.
Tatiana VinichenkoThe Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
Shufang ZhangThe Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
Christoph HamelmannUnited Nations Development Programme, Istanbul Regional Hub, Istanbul, Turkey.
Manoela ManovaJoint United Nations Programme on HIV/AIDS, Geneva, Switzerland.
Emiko MasakiThe World Bank Group, Washington DC, United States of America.
David P WilsonThe Kirby Institute, University of New South Wales, Sydney, Australia.
Richard T GrayThe Kirby Institute, University of New South Wales, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite a non-decreasing HIV epidemic, international donors are soon expected to withdraw funding from Kazakhstan. Here we analyze how allocative, implementation, and technical efficiencies could strengthen the national HIV response under assumptions of future budget levels. METHODOLOGY: We used the Optima model to project future scenarios of the HIV epidemic in Kazakhstan that varied in future antiretroviral treatment unit costs and management expenditure-two areas identified for potential cost-reductions. We determined optimal allocations across HIV programs to satisfy either national targets or ambitious targets. For each scenario, we considered two cases of future HIV financing: the 2014 national budget maintained into the future and the 2014 budget without current international investment.

findingsKazakhstan can achieve its national HIV targets with the current budget by (1) optimally re-allocating resources across programs and (2) either securing a 35% [30%-39%] reduction in antiretroviral treatment drug costs or reducing management costs by 44% [36%-58%] of 2014 levels. Alternatively, a combination of antiretroviral treatment and management cost-reductions could be sufficient. Furthermore, Kazakhstan can achieve ambitious targets of halving new infections and AIDS-related deaths by 2020 compared to 2014 levels by attaining a 67% reduction in antiretroviral treatment costs, a 19% [14%-27%] reduction in management costs, and allocating resources optimally. SIGNIFICANCE: With Kazakhstan facing impending donor withdrawal, it is important for the HIV response to achieve more with available resources. This analysis can help to guide HIV response planners in directing available funding to achieve the greatest yield from investments. The key changes recommended were considered realistic by Kazakhstan country representatives.

Indexed as

Financial SupportHealth Plan ImplementationHealth Services Needs and DemandAdolescentAdultAnti-Retroviral AgentsChildChild, PreschoolCost-Benefit AnalysisFemaleHealth Care CostsHIV-1HIV InfectionsHumansInfantInfant, NewbornAnti-Retroviral Agents

Identifiers

PMID28207809
PMCPMC5313190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.